Discover and read the best of Twitter Threads about #hscTnT
Most recents (2)
Here's a question that you might not have considered: how did the dose for #sacubitril/valsartan in #HFrEF get chosen?
Out today is a paper in @JACCJournals led by @RezaMohebiMD that addresses some questions about sac/val dose in HFrEF.
a 🧵
jacc.org/doi/epdf/10.10…
Out today is a paper in @JACCJournals led by @RezaMohebiMD that addresses some questions about sac/val dose in HFrEF.
a 🧵
jacc.org/doi/epdf/10.10…
It's a little known fact that prior to the PH3 PARADIGM trial, a PH2 study in HFrEF was not performed--normally PH2 studies provide target doses for the pivotal outcomes trials.
So how was the dose of sacubitril/valsartan chosen??
So how was the dose of sacubitril/valsartan chosen??
The target dose of 97/103 mg twice daily was selected to achieve serum concentrations of valsartan = to those in Val-HeFT and VALIANT while simultaneously achieving 90% neprilysin inhibition in normal individuals.
New in @JACCJournals w @JJheart_doc on intersection of biomarkers & #SGLT2i in #T2D.
Canagliflozin in #CANVAS
⤵️hs-cTnT & sST2 out to 6yrs
⤵️HF & kidney outcomes irrespective of baseline biomarkers
⤵️MACE particularly in those w multiple abnormal markers
jacc.org/doi/10.1016/j.…
Canagliflozin in #CANVAS
⤵️hs-cTnT & sST2 out to 6yrs
⤵️HF & kidney outcomes irrespective of baseline biomarkers
⤵️MACE particularly in those w multiple abnormal markers
jacc.org/doi/10.1016/j.…
